{"id":29337,"date":"2015-12-01T12:04:36","date_gmt":"2015-12-01T12:04:36","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=29337"},"modified":"2015-12-01T16:43:56","modified_gmt":"2015-12-01T16:43:56","slug":"sofosbuvirvelpatasvir-submitted-to-us-fda-for-hcv-genotype-1-6","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/29337","title":{"rendered":"Sofosbuvir\/velpatasvir submitted to US FDA for HCV genotype 1-6"},"content":{"rendered":"<p><strong>Gilead press statement<\/strong><\/p>\n<p><strong>On 28 October 2015, Gilead submitted a new drug application to the US FDA for a fixed dose combination of sofosbuvir\/velpatasvir.<\/strong><\/p>\n<p>Sofosbuvir is a nucleotide analog polymerase inhibitor that was approved in the US in December 2013 and velpatasvir is an NS5A inhibitor previously developed as GS-5816.<\/p>\n<p>The application is for treatment for HCV genotypes 1 to 6.<\/p>\n<p>The European application is expected before the end of 2015.<\/p>\n<p>Reference:<\/p>\n<p>Gilead press statement. Gilead submits new drug application to U.S. Food and Drug Administration for fixed-dose combination of sofosbuvir\/velpatasvir for treatment of all six genotypes of hepatitis C. (28 October 2015).<br \/>\n<a href=\"http:\/\/www.gilead.com\/news\/press-releases\">http:\/\/www.gilead.com\/news\/press-releases<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead press statement On 28 October 2015, Gilead submitted a new drug application to the US FDA for a fixed dose combination of sofosbuvir\/velpatasvir. Sofosbuvir is a nucleotide analog polymerase inhibitor that was approved in the US in December 2013 &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-29337","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=29337"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29337\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=29337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=29337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=29337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}